The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Guyn Kim - BMO Capital Markets Equity Research - Analyst
: First, I think for Vimal, the Phase Ib study for 701, what kind of biomarker data are you collecting for these dose cohorts and for potential signals
of inflammation or immune activation? And will you provide that -- those results when you report the safety for cohort 2 later this year?
Question: Guyn Kim - BMO Capital Markets Equity Research - Analyst
: Okay, great. And in the first cohort, how active is the 0.4 milligram dose? And the efficacy signs that you saw of stable disease, do you consider that
meaningful? And how much of a step-up do you -- would you expect to see in the 0.6 milligram dose?
without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.
NOVEMBER 14, 2019 / 1:30PM, BTAI.OQ - Q3 2019 BioXcel Therapeutics Inc Earnings Call
Question: Guyn Kim - BMO Capital Markets Equity Research - Analyst
: Okay. And for 501, what is left to do in the start-up efforts to the clinical -- Phase III clinical trial before you could start screening and enrolling
patients?
Question: Guyn Kim - BMO Capital Markets Equity Research - Analyst
: And maybe you could talk a little bit about your commercialization strategy for 501. Will you be looking for regional partners, size of sales force,
and what kind of infrastructure you would need?
Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst
: I have a couple of questions. The first one is on 501. At what point do you expect to have more clarity on scheduling of the end of Phase II meeting
with the FDA?
without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.
NOVEMBER 14, 2019 / 1:30PM, BTAI.OQ - Q3 2019 BioXcel Therapeutics Inc Earnings Call
Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst
: Sure. And then my next question is on 701. We've seen fledgling safety data there. And we know you're focused on pancreatic and NEPC or tNEPC,
but this innate immunity activators has potential other uses. At what point do you think that you can explore more potential combinations without
sort of distracting yourself from the effort that you have already in place?
Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst
: Got it. And then my last question, again on 701. On the triple combo study in pancreatic cancer, how long do you expect the Nektar and Pfizer
safety run-in trial to last so you can get going on the triple combo?
| 
